Mark Livingston Sells 8,275 Shares of Progyny (NASDAQ:PGNY) Stock

Posted by on May 23rd, 2026

Progyny, Inc. (NASDAQ:PGNY – Get Free Report) CFO Mark Livingston sold 8,275 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $25.50, for a total transaction of $211,012.50. Following the completion of the transaction, the chief financial officer owned 79,063 shares in the company, valued at approximately $2,016,106.50. The trade was a 9.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Performance

Progyny stock opened at $24.88 on Friday. The firm’s 50-day moving average is $19.06 and its 200-day moving average is $22.03. Progyny, Inc. has a 1 year low of $16.10 and a 1 year high of $28.75. The company has a market cap of $1.95 billion, a P/E ratio of 32.31, a PEG ratio of 1.31 and a beta of 0.91.

Progyny (NASDAQ:PGNY – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.47 million. During the same period last year, the firm posted $0.17 EPS. The company’s revenue for the quarter was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, sell-side analysts predict that Progyny, Inc. will post 1.12 earnings per share for the current year.

Institutional Trading of Progyny

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Progyny by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock valued at $217,484,000 after purchasing an additional 235,513 shares during the last quarter. State Street Corp lifted its position in Progyny by 1.5% in the 4th quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after purchasing an additional 44,642 shares during the last quarter. Fort Washington Investment Advisors Inc. OH lifted its position in Progyny by 46.9% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after purchasing an additional 859,289 shares during the last quarter. Wellington Management Group LLP increased its stake in Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after buying an additional 1,621,688 shares during the period. Finally, Ameriprise Financial Inc. raised its position in shares of Progyny by 37.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after buying an additional 545,431 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Canaccord Genuity Group upgraded shares of Progyny from a “hold” rating to a “buy” rating and lifted their price objective for the company from $19.00 to $30.00 in a research report on Tuesday. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price objective on shares of Progyny in a research report on Friday, March 6th. Truist Financial lifted their price objective on shares of Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Finally, KeyCorp cut their price objective on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Progyny presently has an average rating of “Moderate Buy” and a consensus price target of $29.55.

Read Our Latest Stock Analysis on Progyny

About Progyny

(Get Free Report)

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

Featured Articles

Insider Buying and Selling by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.